Overview

Safety Study of Amphinex Based Photochemical Internalisation (PCI) of Bleomycin in Patients With Cutaneous Cancer

Status:
Completed
Trial end date:
2011-05-01
Target enrollment:
Participant gender:
Summary
This study is an open, non- randomized, phase I, dose-escalating study to evaluate the safety and tolerance of Amphinex based PCI of bleomycin in patients with local recurrent or advanced/metastatic, cutaneous or sub-cutaneous malignancies.
Phase:
Phase 1
Details
Lead Sponsor:
PCI Biotech AS
Treatments:
Bleomycin